RxDoctor Payments Data

Robert Gonzalez Fernandez, MD

Cardiovascular Disease · Rio Piedras, PRNPI 1821006503

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (45.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Abbott at 39.8% of the total. Reporting peaked in 2019 at $5,174 and has fallen 98.6% since, to $75 in 2025.

$10,541in general payments, 2019–2025

Across 164 payments — averaging $64.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Philips North America LLC$3K
  • Medtronic$2K
  • Boston Scientific$629
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$111
  • Johnson & Johnson$78
  • plus $227 from 5 others

What the payments were for

  • Consulting fees$1,95018%
  • Travel & lodging$4,76345%
  • Food & beverage$3,82836%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,541 in reported general payments places this provider in the 80th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$8,132
Medicare patients
23
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol133$89,417
XareltoRivaroxaban126$65,973
BrilintaTicagrelor95$51,691
EliquisApixaban70$44,663
Repatha SureclickEvolocumab47$26,432
JardianceEmpagliflozin17$12,194
SynthroidLevothyroxine Sodium127$8,178
Candesartan Cilexetil38$2,910
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid24$2,400
Amiodarone Hcl97$2,331
Enalapril Maleate86$2,168
Metoprolol Succinate159$2,103
Atorvastatin Calcium250$2,045
ClopidogrelClopidogrel Bisulfate144$1,354
Rosuvastatin Calcium150$1,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$62$141,107228 claims
Johnson & JohnsonXarelto$78$65,973126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Rio Piedras

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →